oral QD myosin inhibitor (IC50 = 1.4 µM)

Ph. II candidate for cardiomyopathy (5-30 mg)

from HTS w/ bovine cardiac muscle myofibrils

Journal of Medicinal Chemistry

Cytokinetics, South San Francisco, CA

Chemical structure of molecule Aficamten

The Cytokinetics next-generation myosin inhibitor, aficamten, is a phase II candidate for genetic hypertrophic cardiomyopathies, and is orally dosed between 5-30 mg QD. It follows BMS’s mavacamten (acquired from Myokardia in…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: